Company: CYTK
Filing Date: 2025-03-31
Form Type: PRE 14A
Source: 0001140361-25-011212
Chunk: 69

Company: CYTOKINETICS INC
Filing Date: 2025-03-31
Form: PRE 14A
Chunk 69
---
LE-HCM; |

| • | achieving site activation and patient enrollment of ACACIA-HCM; |

| • | completion of CMC development activities to enable timely regulatory submissions; |

| • | submission of marketing applications in the United States, European Union, and China; |

| 46 |     | Cytokinetics, Inc.|2025 Proxy Statement |

TABLE OF CONTENTS Executive Compensation

| • | finalize commercial launch development campaign, field deployment plan, and patient support model in preparation of a potential commercial launch in the United States; and |

| • | finalize global value dossier, launch sequencing and distribution model in the European Union. |

| • | Goals attributable to the on-going development of our pipeline of drug candidates accounted for 15% of the total corporate goal. Goals included: |

| • | complete enrollment of Phase 1 study of CK-586 with data supportive of advancing the drug candidate in a Phase 2 trial and commence AMBER HFpEF; |

| • | complete all drug product development activities for CK-586 to enable timely commencement of AMBER-HFpEF; and |

| • | obtain endorsement of our Board for external research opportunity to enable execution of a collaboration/in-licensing deal. |

| • | Goals attributable to our business development & finance department achievements accounted for 25% of the total corporate goal. Goals included: |

| • | Generate at least $650 million in committed capital through business development and/or capital market and/or other financings; and |

| • | End the year 2023 with greater than 24 months of forward cash and manage the Company's operations within its approved budget. |

| • | Goals attributable to our research activities accounted for 10% of the total corporate goal. Goals included: |

| • | Completion of a Go/No-Go assessment of one of the Company's specific early-stage research programs; |

| • | execution of an in-license or partner for one new drug discovery program; and |

| • | achievement of two of the following three objectives: (i) finalize research reports and submit an investigatory drug application for CK-089, (ii) identify a development candidate for the Company's specific early-stage research programs with proof-of-concept efficacy data in a rodent disease model; and (iii) advance one new program to hit-to-lead stage. |

| • | various goals attributable to our ESG activities and programs accounted for 5% of the total corporate goal. |

At the end of each year